In Figure 1 we show also the comparison between 2015 vs. 2016 in terms of reimbursements for trastuzumab (advanced HER2+ gastric cancer), panitumumab, cetuximab (advanced RAS wild type colorectal cancer), and bevacizumab (advanced colorectal cancer). The gene discussed is ERBB2; the disease is colorectal cancer.